June 13, 2025 06:58 AM EDTUpdated 08:50 AM
R&D
China
AI

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

Anna Brown

News Reporter

As­traZeneca is fur­ther tight­en­ing its re­la­tion­ship with Chi­na, an­nounc­ing a new re­search part­ner­ship with CSPC Phar­ma­ceu­ti­cals on Fri­day.

CSPC will re­ceive $110 mil­lion up­front for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

For­mer CEO Anne Wo­j­ci­c­ki wins bid for 23andMe

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times